A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
Status:
Withdrawn
Trial end date:
2024-01-30
Target enrollment:
Participant gender:
Summary
This is a Phase II study of single agent ABC294640. Patients with advanced hepatocellular
carcinoma (HCC) who have experienced tumor progression or unacceptable toxicity on single
agent sorafenib will receive ABC294640 500 mg by mouth twice a day continuously. Patients
will continue on study drug until the development of progressive disease per modified RECIST,
intolerable toxicity, withdrawal of patient consent or other event as outlined in patient
discontinuation.
Phase:
Phase 2
Details
Lead Sponsor:
Medical University of South Carolina RedHill Biopharma Limited
Collaborators:
Apogee Biotechnology Corporation Medical University of South Carolina National Cancer Institute (NCI)